Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) appointed three new Senior Vice Presidents as it advances its next phase of growth, expands its commercial portfolio and progresses its neuroscience pipeline. The moves include hiring Bret Paulson as SVP, Market Access, and promoting David Bradfute to SVP and Global Head of Intellectual Property, and Aaron Vosburgh to SVP, Finance and Accounting.

Paulson will lead global market access strategy and payer relationships. Bradfute will direct global IP strategy and serve as Managing Director of Neurocrine Switzerland GmbH in Basel. Vosburgh will oversee enterprise financial strategy, including capital allocation, long-range planning and portfolio investment alignment.

News Market Reaction – NBIX

+0.93%

+0.93% Session close to close

In the Jul 24 session, NBIX gained 0.93%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

NBIX recorded Net Selling across recent insider activity, with 43,330 shares sold and none bought. F...

Analysis

NBIX recorded Net Selling across recent insider activity, with 43,330 shares sold and none bought. For this leadership change, that platform context adds insider positioning as a risk factor to monitor.

Key Figures

Senior Vice Presidents appointed: 3 Senior Vice Presidents Paulson experience: nearly 30 years Otsuka tenure: more than six years +3 more

6 metrics

Senior Vice Presidents appointed 3 Senior Vice Presidents Leadership announcement

Paulson experience nearly 30 years Biopharmaceutical and insurance industries

Otsuka tenure more than six years Bret Paulson before joining Neurocrine

Bradfute Neurocrine tenure 2017 Joined Neurocrine

Arena Pharmaceuticals career 13-year career David Bradfute before Neurocrine

Vosburgh Neurocrine tenure eight-year Aaron Vosburgh employee tenure

Historical Context

5 past events · Latest: Jul 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 21	Leadership appointment	Positive	-3.5%	Appointed Samir Siddhanti Chief Business Officer and executive Management Committee member
Jul 09	Results scheduling	Neutral	-1.9%	Scheduled second-quarter 2026 results release and conference call
Jul 01	Phase 2 initiation	Positive	+3.9%	Initiated pediatric crinecerfont study enrolling 20 children
Jun 15	Clinical data	Positive	-1.9%	Presented Phase 3 VYKAT XR data showing durable hyperphagia improvements
Jun 15	Clinical data	Positive	-1.9%	Presented preliminary CRENESSITY case-series findings in 15 patients

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent NBIX news reactions more often diverged from favorable or informational announcements than aligned with them.

Key Terms

market access, intellectual property, capital allocation, financial planning and analysis

4 terms

market access financial

"Senior Vice President, Market Access"

Market access is the ability of a company or product to reach and sell to its intended customers, including having the legal permissions, distribution channels, pricing agreements, and reimbursement or payment arrangements needed to actually make sales. Think of it like opening a storefront and having both the keys and the roads that let customers get in — without it a product can exist but won’t generate expected revenue. Investors watch market access because it directly affects how quickly and how much money a product can earn and how risky sales forecasts are.

intellectual property regulatory

"Senior Vice President and Global Head of Intellectual Property"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

capital allocation financial

"align capital allocation, long-range financial planning"

Capital allocation is the process of deciding how a company or individual uses their money to grow, pay bills, save, or invest. It matters because good decisions can help build wealth and ensure resources are used wisely, while poor choices can limit growth or cause financial problems. Think of it like managing your allowance—deciding whether to spend, save, or invest to meet your goals.

View in glossary

financial planning and analysis financial

"financial planning and analysis capabilities"

Financial planning and analysis is the ongoing process companies use to create budgets, forecast future revenues and costs, and evaluate actual performance against those plans. Think of it as a company’s financial roadmap and compass — it shows where management expects the business to go, flags variances from the plan, and supports decisions about spending, investments, and risk. For investors, strong FP&A provides clearer signals about likely cash flow, profitability, and management’s ability to execute strategy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the industry's strongest neuroscience pipelines. These appointments reflect Neurocrine's continued evolution into a diversified, multi-product biopharmaceutical company positioned to deliver sustainable long-term growth.

The appointments include Bret Paulson, who joins the company as Senior Vice President, Market Access, and the promotions of David Bradfute to Senior Vice President and Global Head of Intellectual Property, and Aaron Vosburgh to Senior Vice President, Finance and Accounting.

"Neurocrine is entering a new phase of growth as we expand our commercial portfolio, advance one of the industry's most productive pipelines and prepare to bring more innovative medicines to patients," said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. "Successfully executing on that opportunity requires exceptional leadership across every function of our company. Bret, Aaron and David each bring outstanding expertise, judgment and a proven ability to build high-performing organizations. Together, they strengthen our ability to execute today while positioning Neurocrine for the opportunities ahead, ultimately enabling us to deliver greater value for patients, healthcare providers and shareholders."

Bret Paulson is an accomplished leader with nearly 30 years of experience in the biopharmaceutical and insurance industries. He will be responsible for shaping and driving Neurocrine's global market access vision, strategy and execution to provide patient access to the company's current and future medicines, while strengthening payer partnerships and reimbursement strategies across an increasingly diversified portfolio. He joins Neurocrine after more than six years at Otsuka Pharmaceutical Companies, most recently as Vice President and Head of Market Access & Channel Strategy. Prior to that, he was Area Vice President, National Accounts at Horizon after working in the commercial organizations at Schering Plough, Eli Lilly & Company, and Amgen. Paulson earned a Bachelor of Arts in Asian studies from Brigham Young University.

David Bradfute, who joined Neurocrine in 2017, has been promoted to Senior Vice President and Global Head of Intellectual Property and will also serve as Managing Director of Neurocrine Switzerland GmbH, based in the company's Basel, Switzerland, office. In his expanded role, Bradfute will lead the company's global intellectual property strategy and oversee the protection of Neurocrine's products, diversified portfolio, technology platforms, and scientific innovations. Before joining Neurocrine, Bradfute held leadership roles across the healthcare and life sciences industry, including a 13-year career at Arena Pharmaceuticals and later as Head of Legal and Intellectual Property at Sanford Burnham Prebys Medical Discovery Institute. He earned a bachelor's degree in biochemistry from Swarthmore College, master's and doctoral degrees in biological sciences from Stanford University, and a Juris Doctor from Stanford Law School.

Aaron Vosburgh, an eight-year Neurocrine employee, will oversee enterprise financial strategy, partnering with executive leadership to align capital allocation, long-range financial planning and portfolio investments with Neurocrine's strategy to advance innovation and deliver new therapies to patients. While at Neurocrine, he has helped build, scale and strengthen the company's accounting, finance, tax, treasury, and financial planning and analysis capabilities while serving as a strategic advisor on many of the company's most important financial decisions. Prior to joining Neurocrine, Vosburgh held senior finance leadership roles at Applied Proteomics, Synthetic Genomics, Verenium Corporation, and Natural Alternatives International, following the start of his career at Ernst & Young. He is a Certified Public Accountant (inactive) and earned a Bachelor of Arts in Accounting from the University of San Diego.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE, are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-key-leadership-hiring-promotions-302832679.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What leadership changes did Neurocrine Biosciences (NBIX) announce on July 23, 2026?

Neurocrine Biosciences announced three Senior Vice President appointments on July 23, 2026. According to Neurocrine Biosciences, the company hired Bret Paulson as SVP, Market Access, and promoted David Bradfute to SVP and Global Head of Intellectual Property and Aaron Vosburgh to SVP, Finance and Accounting.

Who is the new Senior Vice President of Market Access at Neurocrine Biosciences (NBIX)?

Bret Paulson was appointed Senior Vice President, Market Access at Neurocrine Biosciences. According to Neurocrine Biosciences, he will shape and drive global market access vision, strategy and execution, focusing on patient access, payer partnerships and reimbursement for the company’s current and future medicines across a diversified portfolio.

What is David Bradfute’s new role at Neurocrine Biosciences (NBIX)?

David Bradfute has been promoted to Senior Vice President and Global Head of Intellectual Property at Neurocrine Biosciences. According to Neurocrine Biosciences, he will lead global IP strategy, protect products and innovations, and serve as Managing Director of Neurocrine Switzerland GmbH in Basel, Switzerland.

What responsibilities will Aaron Vosburgh have as SVP, Finance and Accounting at Neurocrine Biosciences (NBIX)?

Aaron Vosburgh will oversee enterprise financial strategy as SVP, Finance and Accounting at Neurocrine Biosciences. According to Neurocrine Biosciences, he will partner with executive leadership on capital allocation, long-range financial planning and portfolio investments to support innovation and delivery of new therapies to patients.

How do the new Senior Vice President appointments support Neurocrine Biosciences’ (NBIX) growth strategy?

The new SVP appointments are intended to strengthen leadership across key functions supporting growth. According to Neurocrine Biosciences, these roles in market access, intellectual property, and finance are aligned with expanding its commercial portfolio, advancing a broad neuroscience pipeline and delivering sustainable long-term growth.

What experience does Bret Paulson bring to Neurocrine Biosciences (NBIX) as SVP, Market Access?

Bret Paulson brings nearly 30 years of biopharmaceutical and insurance industry experience to Neurocrine Biosciences. According to Neurocrine Biosciences, he previously held senior market access and commercial roles at Otsuka, Horizon, Schering Plough, Eli Lilly & Company and Amgen, and will lead global market access strategy.